Perceiva sirolimus: Completed Phase II enrollment

MacuSight completed enrollment of 62 previously treated patients in the placebo-controlled, dose-ranging, U.S. Phase II EMERALD trial evaluating subconjunctival injections of Perceiva in combination w...